english.prescrire.org > Prescrire International > N°221 - December 2020

n°221

December 2020

Issue Contents
Editorial

Free  An exemplary initiative

p.283

New Products


Fexinidazole (Fexinidazole Winthrop°) and sleeping sickness caused by Trypanosoma brucei gambiense

p.285-289
Effective and more convenient than injectable treatments

Editors' opinion. Development of fexinidazole: a product of exemplary collaboration

p.289

Free  Betibeglogene autotemcel (Zynteglo°) in certain forms of severe beta thalassaemia

p.290-291
An option for achieving transfusion independence in the absence of a compatible donor

Free  Editors' opinion. The European Priority Medicines ("Prime") scheme cements industry influence over early marketing authorisation

p.291

Meropenem + vaborbactam (Vaborem°) and serious infections

p.292-293
A backup option in cases of carbapenem resistance

Volanesorsen (Waylivra°) and familial chylo­micronemia syndrome

p.294

INN Common stem: -penem

p.294

Adverse Effects


Drug-induced pericarditis

p.295-298

Citalopram + omeprazole: sudden cardiac death

p.298

Bimatoprost and similar eye drops: enophthalmos

p.299-300

Mecasermin: benign and malignant tumours

p.300

Degarelix: rhabdomyolysis

p.300

Reviews


Relief of moderate nociceptive pain in breastfeeding women

p.301-302
Non-pharmacological measures first, then paracetamol or ibuprofen

Lung cancer with a del19 EGFR mutation

p.302
Survival extended with osimertinib as first-line therapy

Outlook


Free  Drug research: public funding, private profits

p.303-306

Oxycontin°: regulation conferred protection in some states in the US

p.306

Free  Mediator°: all wrong from the very start

p.307

Masthead


Free  Masthead

p.282

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe